Non-invasive Prenatal Tests (NIPT) are new generation tests for screening and detection of chromosomal abnormalities during pregnancy. The NIPTs are performed on a maternal blood sample and evaluate the risk of the most common chromosomal alterations through the analysis of free fetal DNA circulating in the mother's blood.
Advanced maternal age increases the risk for the trisomies 21, 18, 13
In addition to genetic predisposition, advanced maternal age increases the risk of pregnancy at risk. This graph shows the correlation between the exponential growth of the risk of some trisomies and the maternal age.
During pregnancy, fragments of free fetal DNA circulate in the mother's blood. Fetal DNA is detectable starting from the 5th week of gestation and its concentration increases during the following weeks. The amount of fetal DNA present in the maternal bloodstream from the 11th week of gestation (12th week for twin pregnancies) is sufficient to perform the test and ensure accurate results.
Genechron provides the only non-invasive prenatal test of fetal DNA with CE mark (CE-IVD) for trisomies 21, 18 and 13 that can also detect the aneuploidies of all the chromosomes, different microdeletion syndromes and the sex of the unborn child.
Non-invasive Prenatal Test, by free fetal DNA analysis isolated from maternal blood for the screening of aneuploidy related to chromosomes 13, 18, 21, X and Y + determination of fetal sex (optional). With genetic counseling
It is the non-invasive prenatal screening test (NIPT) which analyzes free fetal DNA (cfDNA) isolated from maternal blood. It detects the common aneuploidies (Trisomy 21, 18, 13 and the aneuploidy of the sex chromosomes) and less common (eg Trisomies 9,16, 22) and structural chromosomal alterations (segmental duplications and deletions) for each chromosome of the fetal karyotype. The determination of sex is optional. With genetic counseling
For more information: